PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 2011 October 3; 121(10): 4180–4191.
Published online 2011 September 19. doi:  10.1172/JCI46139
PMCID: PMC3195461

Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice

Abstract

Mast cell degranulation is important in the pathogenesis of anaphylaxis and allergic disorders. Many animal venoms contain components that can induce mast cell degranulation, and this has been thought to contribute to the pathology and mortality caused by envenomation. However, we recently reported evidence that mast cells can enhance the resistance of mice to the venoms of certain snakes and that mouse mast cell–derived carboxypeptidase A3 (CPA3) can contribute to this effect. Here, we investigated whether mast cells can enhance resistance to the venom of the Gila monster, a toxic component of that venom (helodermin), and the structurally similar mammalian peptide, vasoactive intestinal polypeptide (VIP). Using 2 types of mast cell–deficient mice, as well as mice selectively lacking CPA3 activity or the chymase mouse mast cell protease-4 (MCPT4), we found that mast cells and MCPT4, which can degrade helodermin, can enhance host resistance to the toxicity of Gila monster venom. Mast cells and MCPT4 also can limit the toxicity associated with high concentrations of VIP and can reduce the morbidity and mortality induced by venoms from 2 species of scorpions. Our findings support the notion that mast cells can enhance innate defense by degradation of diverse animal toxins and that release of MCPT4, in addition to CPA3, can contribute to this mast cell function.

Introduction

In addition to their roles as effector cells in anaphylaxis and allergic disorders, there is evidence that mast cells can enhance innate host defense through functions such as directly killing pathogens or augmenting pathogen-induced inflammatory responses (13) or by degrading potentially toxic endogenous peptides generated in such settings (4, 5). We recently reported that mast cells also can enhance resistance in mice to the morbidity and mortality induced by the whole venoms of 3 species of snakes and the honeybee (6). In the case of the Israeli mole viper, Atractaspis engaddensis, pharmacological evidence and studies in mice containing mast cells treated with shRNA to reduce expression of carboxypeptidase A3 (CPA3, which also has been designated mouse mast cell–derived carboxypeptidase A3) activity suggested that CPA3 is important for reducing the toxicity of both the whole venom and its major toxin, sarafotoxin 6b (6). The essential role for CPA3 in degrading and enhancing resistance to sarafotoxin 6b was demonstrated by showing that mutant mice selectively lacking CPA3 activity exhibited impaired resistance to the lethal effects of that venom peptide (7). However, the extent to which mast cells and their specific products might be able to enhance resistance to other animal venoms or exogenous toxins remained to be determined.

Notably, both sarafotoxin 6b (6) and its structurally related mammalian molecule, the vasoconstrictor peptide endothelin-1 (ET-1) (8), can induce mast cell degranulation in mice, and mast cells (4, 7) and mast cell–derived CPA3 (6, 7) can enhance resistance to the morbidity and mortality associated with ET-1 or sarafotoxin 6b. We therefore searched for other examples of reptile venoms that contain peptides that are structurally similar to mammalian peptides known to activate mast cells. We decided to investigate the venom of the poisonous lizard the Gila monster (Heloderma suspectum) because its venom contains the toxin helodermin, which has structural and functional similarities to mammalian vasoactive intestinal polypeptide (VIP) (912).

The Gila monster is native to the southwestern United States and northern Mexico. In contrast to snake envenomation, human bites by lizards are relatively rare but appear to be increasing in parallel with improvements in captive-breeding techniques (13). Envenomation by the Gila monster is not ordinarily fatal to adult humans, but results in intense pain, edema, weakness, and nausea associated with hypotension or tachycardia and can even cause anaphylactic shock or myocardial infarction (1317). These signs and symptoms probably reflect powerful physiological effects of the kallikrein-like peptides and other bioactive peptides in Heloderma venom (17, 18). In the most severe reported case of Gila monster envenomation (19), the victim’s signs and symptoms were reported to be similar to those seen in pancreatic cholera, a condition produced by VIP-secreting tumors (also known as VIPomas), which is also called the watery diarrhea, hypokalemia, and achlorhydria (WDHA) syndrome (14, 17). The signs and symptoms observed in that case are consistent with the results of recent studies of molecular evolution in suggesting an important role for VIP-like bioactive peptides in the pathology of Gila monster envenomation (14, 17, 20).

Of the 2 VIP-related peptides that have been isolated from Heloderma venoms, helospectin (exendin-1) and helodermin (exendin-2), the 35–amino-acid peptide helodermin is the major VIP-like peptide in Gila monster venom (21). Helodermin, the first VIP-related peptide identified in an animal other than a mammal or bird (911), is a hypotensive toxin that can bind to mammalian VIP receptors (10, 22), a property that is likely to have developed as a result of convergent evolution (12). In addition to its vasodepressor activity, helodermin is thought to be responsible, at least in part, for the tachycardia seen in human Gila monster envenomation (18, 23). Previous reports have provided evidence for the existence of complex interactions between mast cells and VIP, in that mast cells can produce VIP (24, 25) as well as express VIP receptors (2629) and degranulate in response to VIP (27, 29), but mast cell–derived proteases can degrade VIP (30, 31). However, to our knowledge, the possible interactions between mast cells and helodermin have not yet been studied.

We investigated whether mast cells and the mast cell–derived proteases mouse mast cell protease-4 (MCPT4, which has also been designated mMCP-4), MCPT5 (which has also been designated mMCP-5), and CPA3 might influence the morbidity and mortality induced by H. suspectum venom, by helodermin, or by mammalian VIP. Venoms derived from several animal species other than reptiles and honeybees, including those from scorpions (32), also have been shown to activate mast cells. We therefore also tested venoms from 2 species of medically important scorpions, the deathstalker (yellow) scorpion (Leiurus quinquestriatus hebraeus) (3335) and the Arizona bark scorpion (Centruroides exilicauda) (3537). By using mast cell–engrafted genetically mast cell–deficient WBB6F1-KitW/W-v and C57BL/6-KitW-sh/W-sh mice as well as mice either selectively lacking MCPT4 or CPA3 plus MCPT5 or bearing an enzymatically inactive form of CPA3, we demonstrate that mast cells can enhance host resistance to the toxicity of Gila monster and scorpion venoms, and VIP, predominantly through MCPT4-dependent mechanisms.

Results

Mast cells and MCPT4 can enhance resistance to H. suspectum venom–induced morbidity and mortality.

We first administered 2 different amounts of H. suspectum venom (5 and 50 μg) intradermally (i.d.) in the ear pinnae of WT and genetically mast cell–deficient mice. We used the ear pinna as the site of venom injection because most reptile bites involve the skin and subcutaneous tissue and also because this relatively hairless area is useful for local mast cell–engraftment experiments. All mice survived challenge with 5 μg of H. suspectum venom (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI46139DS1). Most WT Kit+/+ mice also survived challenge with 50 μg of venom but some exhibited hypothermia, whereas 50 μg of H. suspectum venom induced severe hypothermia and death in all of the mast cell–deficient WBB6F1-KitW/W-v mice or C57BL/6-KitW-sh/W-sh mice tested (Supplemental Figure 1). In this and all subsequent experiments, mice that survived for 24 hours after injection of venom appeared to recover fully. Based on these results, we decided to use 25 μg of H. suspectum venom for subsequent experiments.

When challenged with 25 μg of H. suspectum venom i.d. in 1 ear, mast cell–deficient KitW/W-v mice developed severe hypothermia and 65% of mice died within 24 hours, whereas the corresponding WT Kit+/+ mice exhibited only a slight drop in body temperature and all of the mice survived and fully recovered (Figure (Figure1A).1A). We then examined mast cell–deficient mice that had been engrafted with bone marrow–derived cultured mast cells (BMCMCs) from WBB6F1-Kit+/+ mice (WT BMCMC→KitW/W-v mice) (38, 39). The local engraftment of mast cell–deficient mice with WT BMCMCs in 1 ear pinna resulted in levels of resistance to the mortality induced by 25 μg of H. suspectum venom that were statistically indistinguishable from those in the corresponding WT mice (Figure (Figure1A).1A). Similar results were obtained when these experiments were repeated with WT C57BL/6-Kit+/+ mice, C57BL/6-KitW-sh/W-sh mice, and WT BMCMC-engrafted KitW-sh/W-sh mice (Figure (Figure1B). 1B).

Figure 1
Mast cells can diminish H. suspectum venom–induced (H.s. venom–induced) hypothermia and mortality through MCPT4-dependent mechanisms.

MCPT4 is considered to be the mouse functional counterpart of human chymase (40), and CPA3 is the only carboxypeptidase expressed in mast cells. To assess whether MCPT4 or CPA3 might contribute to the mast cell’s ability to reduce the toxicity of H. suspectum venom, we tested mice that either selectively lacked MCPT4 (Mcpt4–/– mice) (41) or that contained only a catalytically inactive form of CPA3 (Cpa3Y356L,E378A mice) (7). We found that WT, Mcpt4–/–, and Cpa3Y356L,E378A mice contained nearly equal numbers of mast cells in the ear pinnae (Supplemental Figure 2). Moreover, intradermal injection of H. suspectum venom induced levels of mild hypothermia in Cpa3Y356L,E378A mice that were similar to those in the corresponding WT control mice, and none of the Cpa3Y356L,E378A mice and only 1 out of 15 WT mice died (Figure (Figure1C).1C). In contrast, identically challenged Mcpt4–/– mice developed severe hypothermia and 6 of 15 (40%) died (Figure (Figure1C). 1C).

To determine whether mast cells and mast cell MCPT4 could enhance resistance to H. suspectum venom even when such mast cells were engrafted only in 1 ear pinna of genetically mast cell–deficient KitW-sh/W-sh mice, we injected 25 μg of H. suspectum venom i.d. into the ear pinnae of KitW-sh/W-sh mice that had been engrafted at that site with BMCMCs derived from either WT or Mcpt4–/– mice. Although WT and Mcpt4–/– BMCMC-engrafted mice showed similar numbers of mast cells in ear pinnae (Supplemental Figure 2), those that had received Mcpt4–/– BMCMCs developed more severe hypothermia and 6 of 14 (43%) died, versus only 2 of 18 WT BMCMC→KitW-sh/W-sh mice (Figure (Figure1B).1B). It is likely that MCPT4 expression is restricted largely or even exclusively to mast cells (40, 42, 43), and the data in Figure Figure1B1B support this conclusion by showing that a defect in host resistance to H. suspectum venom can be observed in mice in which only the engrafted mast cells were genetically unable to produce MCPT4. We next quantified to what extent H. suspectum venom can induce degranulation of skin mast cells in the various mice used in our experiments, as this will result in the local secretion of proteases and other constituents of the mast cells’ granules. Intradermal injection of H. suspectum venom, but not vehicle, induced extensive degranulation of mast cells in the ear pinnae, as assessed 1 hour after the injection (Figure (Figure1D),1D), and the extent of such mast cell degranulation did not differ in WT, Mcpt4–/–, and Cpa3Y356L,E378A mice (Figure (Figure1E). 1E).

Taken together, our results indicate that H. suspectum venom can induce extensive degranulation of dermal mast cells in mice, that dermal mast cells can enhance the resistance of mice to the morbidity and mortality induced by i.d. injection of H. suspectum venom, and that MCPT4, but not CPA3, can contribute substantially to the ability of mast cells to limit the toxicity of H. suspectum venom. These findings are particularly interesting in that mast cell– and mast cell–MCPT4–dependent enhancement of host resistance to H. suspectum venom was observed in mice in which mast cells had been engrafted only in the ear pinna challenged with the venom. Thus, such mast cell–dependent enhancement of host resistance did not require systemic engraftment of mast cells. However, we noted that both Mcpt4–/– mice (Figure (Figure1C)1C) and Mcpt4–/– BMCMC→KitW-sh/W-sh mice (Figure (Figure1B)1B) developed less hypothermia than did KitW-sh/W-sh mice (Figure (Figure1B).1B). This might reflect the contribution of a mast cell–dependent but MCPT4-independent mechanism that can contribute to host resistance in this model and/or the presence of phenotypic abnormalities in KitW-sh/W-sh mice that reduce their resistance to this venom independently of their mast cell deficiency.

Mast cells and MCPT4 can enhance resistance to helodermin-induced morbidity.

While Gila monster venom contains many different toxins, we were particularly interested in whether the toxicity of helodermin, the major VIP-like peptide in Gila monster venom, also might be diminished in a mast cell–dependent manner. All mast cell–deficient KitW-sh/W-sh mice injected i.d. with 5 nmol (19.2 μg) of helodermin developed sustained hypothermia and diarrhea (a finding also observed in the most severe case of Gila monster envenomation in humans; ref. 19), whereas identically challenged WT mice developed only mild, transient hypothermia and exhibited low rates of diarrhea (20%) (Figure (Figure2A).2A). Engraftment of mast cell–deficient mice with WT BMCMCs at the site later used for i.d. injection of helodermin largely restored WT levels of resistance against helodermin-induced hypothermia and diarrhea (Figure (Figure2A). 2A).

Figure 2
Mast cells and MCPT4 can diminish helodermin-induced hypothermia and diarrhea in mice.

To assess the extent to which the differences in the responses of mast cell–deficient and WT mice might reflect the lack of mast cell proteases in mast cell–deficient mice, we examined Mcpt4–/– and Cpa3Y356L,E378A mice. Cpa3Y356L,E378A mice responded to i.d. injection of 5 nmol of helodermin with mild hypothermia similar to (albeit significantly more than) that of WT mice, and diarrhea developed in a larger percentage of Cpa3Y356L,E378A than WT mice; however, with the numbers of mice tested, this result was not statistically significant (Figure (Figure2B).2B). In contrast, Mcpt4–/– mice exhibited a more substantial drop in temperature and all developed diarrhea (P < 0.005 vs. WT mice) (Figure (Figure2B).2B). Indeed, Mcpt4–/– BMCMC→KitW-sh/W-sh mice, like mast cell–deficient KitW-sh/W-sh mice, exhibited sustained hypothermia and diarrhea (Figure (Figure2A). 2A).

Mast cells and MCPT4 can limit the toxicity of VIP in vivo.

We previously reported evidence that, in mice, mast cells can enhance resistance to the morbidity and mortality of both ET-1 (4, 7) and sarafotoxin 6b, the structurally similar peptide found in the venom of the poisonous snake, A. engaddensis (6, 7), and that the major protease responsible for degrading ET-1 and sarafotoxin 6b is CPA3 (6, 7). Other mast cell–derived proteases, including chymase, have been reported to degrade VIP in vitro (30, 31). We therefore examined whether mast cells can enhance host resistance to VIP, a mammalian peptide that is structurally similar to helodermin.

When challenged i.d. with 5 nmol (16.6 μg) of VIP, mast cell–deficient KitW-sh/W-sh mice developed prolonged hypothermia and diarrhea (a finding also observed in patients with VIPoma; refs. 44, 45), whereas the corresponding WT Kit+/+ mice quickly recovered from their hypothermia and few exhibited diarrhea (Figure (Figure3A).3A). KitW-sh/W-sh and mice engrafted with WT mast cells exhibited significantly enhanced resistance to VIP-induced hypothermia and diarrhea (Figure (Figure3A).3A). In response to challenge with 5 nmol of VIP, hypothermia and rates of diarrhea in Cpa3Y356L,E378A mice were not statistically different from those in WT mice, although the rate of diarrhea was higher than in WT mice. In contrast, compared with WT mice, Mcpt4–/– mice developed a more substantial reduction in body temperature and a higher rate of diarrhea (Figure (Figure3B).3B). Furthermore, Mcpt4–/– BMCMC–engrafted KitW-sh/W-sh mice exhibited hypothermia responses that were intermediate between those of the WT BMCMC-engrafted mice and KitW-sh/W-sh mice, and 100% of the Mcpt4–/– BMCMC→KitW-sh/W-sh mice, like the mast cell–deficient KitW-sh/W-sh mice, developed diarrhea (Figure (Figure3A).3A). Like i.d. injection of H. suspectum venom, i.d. injection of helodermin or VIP also induced extensive degranulation of mast cells in the ear pinnae, and the extent of such mast cell degranulation did not differ among the groups of mice tested (Supplemental Figure 3). Thus, our experiments in genetically mast cell–deficient mice indicate that mast cells can limit the magnitude of the systemic toxicity induced by either helodermin or VIP. Moreover, our work with mice deficient in MCPT4 or lacking CPA3 protease activity indicates that MCPT4, but not CPA3, significantly contributes to the mast cell’s ability to enhance resistance to helodermin or VIP.

Figure 3
Mast cells and MCPT4 can diminish VIP-induced hypothermia and diarrhea in mice.

Activation of mast cells by helodermin or VIP via VIP receptors.

To assess how helodermin or VIP interacts with mast cells, we used a pharmaceutical approach employing the specific VIP receptor antagonist VIP6–28 (46). Consistent with the results of our assessment of mast cell degranulation in vivo (Supplemental Figure 3), we found that helodermin (Figure (Figure4A)4A) and VIP (Figure (Figure4B)4B) can induce β-hexosaminidase release from purified mouse peritoneal mast cells (PMCs; purity > 75%) in a dose-dependent manner and that the extent of such mast cell activation did not differ between PMCs from WT and Mcpt4–/– mice. Moreover, pretreatment with VIP6–28 significantly inhibited helodermin- or VIP-induced β-hexosaminidase release from PMCs, indicating that these toxins can activate mast cells at least partly through VIP receptors. Our findings are consistent with the results of prior work indicating that various mast cell populations can express receptors for VIP, which, depending on the type of mast cell population, may be VPAC1 (formerly designated VIP receptor type I/PACAP receptor type II) (26, 27) or VPAC2 (formerly designated VIP receptor type II/PACAP receptor type III) (28, 29).

Figure 4
Helodermin (Helo) and VIP can activate mast cells at least partly through VIP receptors.

Evidence that MCPT4 contributes to mast cell–dependent degradation of VIP in vitro and in vivo.

To evaluate directly the importance of mast cell–derived MCPT4 in degrading VIP, VIP (125 μM) was incubated ex vivo with medium alone or with medium containing purified PMCs from WT mice (WT PMCs), Mcpt4–/– mice (Mcpt4–/– PMCs), or Cpa3Y356L,E378A mice (Cpa3Y356L,E378A PMCs), and the amount of remaining VIP was measured by ELISA. WT PMCs and Cpa3Y356L,E378A PMCs almost completely degraded VIP under these conditions, whereas Mcpt4–/– PMCs exhibited little or no ability to degrade VIP (Figure (Figure5). 5).

Figure 5
Mast cell chymase (MCPT4) contributes to mast cell–dependent degradation of VIP.

To assess the role of MCPT4 in the degradation of VIP in vivo, we measured the levels of VIP in blood and ear tissue after i.d. injection of 5 nmol of helodermin versus VIP in the ear pinnae of WT mice, mast cell–deficient KitW-sh/W-sh mice, WT BMCMC-engrafted KitW-sh/W-sh mice, and Mcpt4–/– mice (Supplemental Figure 4). After injection of VIP, the amount of VIP in either sera or ears was significantly higher in KitW-sh/W-sh mice than in WT mice or WT BMCMC→KitW-sh/W-sh mice, whereas Mcpt4–/– mice exhibited significantly higher concentrations of VIP in the sera and injected ears than did WT mice, but the levels were not as high as those in KitW-sh/W-sh mice. The latter result suggests that mast cell functions other than those related to the cell’s content of MCPT4 may contribute to the ability of mast cells to reduce levels of VIP in vivo. We also found that the concentrations of VIP in the sera and ears did not differ between WT mice injected with helodermin or control mice not injected with peptide. These results indicate that MCPT4 contributes, at least in part, to the mast cell–dependent degradation of VIP in vivo as well as in vitro, and that i.d. injection of helodermin does not detectably increase local or systemic concentrations of endogenous VIP.

Mass spectrometry evidence that MCPT4 can degrade VIP or helodermin.

Since we could not detect helodermin using our ELISA for VIP, we performed mass spectrometry on samples prepared in the same way as described above for analysis by ELISA. We identified 4 cleavage sites in VIP (Figure (Figure6A)6A) and 5 in helodermin (Figure (Figure6B)6B) that were detected after incubation of the peptides with purified WT PMCs but not Mcpt4–/– PMCs. Two of the cleavage sites we identified, 1 in VIP and 2 in helodermin (at a Phe-Thr and a Tyr-Leu), were previously predicted to be susceptible to cleavage by chymase (47), and 1 of these (at Tyr-Leu) is a previously reported chymase cleavage site in VIP (30). We also found a single cleavage site in VIP that was observed after incubation of the peptide with PMCs from either WT or Mcpt4–/– mice (Figure (Figure6A),6A), probably reflecting the action of a mast cell–associated protease other than MCPT4, perhaps tryptase, which has been reported to cleave VIP at Arg-Lys (30, 31).

Figure 6
Mast cell chymase can degrade either VIP or helodermin.

Evidence that MCPT5 does not contribute significantly to the mast cell’s ability to detoxify helodermin or VIP.

By mass spectrometry, we found Val and Ala cleavage sites in VIP or helodermin that would be predicted to be susceptible to MCPT5 (which has elastolytic activity) (48) but not to the chymase MCPT4 (47). We previously showed that the absence of MCPT4 in Mcpt4–/– mice does not result in reduced expression or storage of other mast cell proteases (including MCPT5) (41, 49, 50). However, to investigate the potential role of MCPT5 in degrading VIP or helodermin, we tested the ability of PMCs from Cpa3-deficient (Cpa3–/–) mice, which lack both CPA3 and MCPT5 proteins (51), to degrade VIP in vitro. We found that Cpa3–/– PMCs, like WT PMCs, almost completely degraded VIP under the conditions tested (Figure (Figure7A).7A). We then challenged Cpa3–/– versus WT mice i.d. with 5 nmol (19.2 μg) of helodermin in vivo and found that the body temperature change and the rate of diarrhea in Cpa3–/– mice injected with helodermin were not statistically different from those in the identically treated WT mice (Figure (Figure7B).7B). We also confirmed that the number of mast cells, as well as the extent of helodermin-induced mast cell degranulation in the ear pinnae, in Cpa3–/– mice were similar to those in the other groups of mice tested (Supplemental Figures 2 and 3). These results indicate that the contributions of MCPT5 to the degradation of helodermin or VIP are likely to be relatively minor compared with the effects of MCPT4. However, as we have speculated previously (40), it is possible that MCPT5 (and perhaps other proteases) can gain access to these substrates once MCPT4 has performed initial cleavages of the peptides.

Figure 7
Evidence that MCPT5 does not contribute significantly to the mast cell’s ability to degrade and detoxify helodermin or VIP.

Mast cells and MCPT4 can limit the toxicity of the venoms of 2 species of scorpion.

To assess the potential roles of mast cells and their proteases in the pathology and mortality induced by venoms from animals other than reptiles, we next tested venoms derived from 2 medically important scorpions, 1 from the Old World, the deathstalker (yellow) scorpion (L. quinquestriatus hebraeus) (3335), and 1 from the New World, the Arizona bark scorpion (C. exilicauda) (3537). Based on results obtained in preliminary experiments to assess the responses of WT or mast cell–deficient mice to various amounts of each type of venom (Supplemental Figure 5), we elected to inject mice with 7.5 μg of each type of venom in subsequent experiments.

Mast cell–deficient KitW/W-v mice injected i.d. with 7.5 μg of L. quin­questriatus hebraeus venom exhibited significantly lower body temperatures than WT mice, and all of them died approximately 1 hour after L. quinquestriatus hebraeus venom injection (Figure (Figure8A).8A). In contrast, all WT Kit+/+ mice survived and fully recovered. Moreover, engraftment of KitW/W-v mice with WT BMCMCs resulted in levels of protection against hypothermia and death that were statistically indistinguishable from those in WT mice (Figure (Figure8A).8A). Similar results were obtained when the same experiments were performed in C57BL/6-Kit+/+, C57BL/6-KitW-sh/W-sh, and WT BMCMC-engrafted KitW-sh/W-sh mice (Figure (Figure8C).8C). Like WT mice, all Cpa3Y356L,E378A mice survived after i.d. injection of 7.5 μg of L. quinquestriatus hebraeus venom, whereas 7 of 16 Mcpt4–/– mice died (Figure (Figure8B).8B). Roughly half (8 of 15) of the Mcpt4–/– BMCMC-engrafted KitW-sh/W-sh mice also died upon injection of L. quinquestriatus hebraeus venom, versus 0 of 12 WT mice and 2 of 15 WT BMCMC-engrafted KitW-sh/W-sh mice (Figure (Figure8C).8C). Similar results were obtained when the various groups of mice were injected i.d. with 7.5 μg of C. exilicauda venom, except that roughly half of the mast cell–deficient mice survived this dose of venom, whereas all mast cell–deficient mice injected with the same amount of L. quinquestriatus hebraeus venom died (Figure (Figure9).9). We also found that, like Gila monster venom, venom from either scorpion induced extensive degranulation of mast cells upon injection into the ear pinnae of WT, Mcpt4–/–, or Cpa3Y356L,E378A mice (Supplemental Figure 6).

Figure 8
Mast cells and MCPT4 can limit the toxicity of deathstalker (yellow) scorpion (L.q.h.).
Figure 9
Mast cells and MCPT4 can limit the toxicity of Arizona bark scorpion (C.e.).

Discussion

We found that 2 types of genetically mast cell–deficient mice, WBB6F1-KitW/W-v and C57BL/6-KitW-sh/W-sh mice, and C57BL/6-Mcpt4–/– mice, were more susceptible than the corresponding WT mice to the morbidity and mortality induced by the i.d. injection of the venoms of the Gila monster or of 2 species of scorpion. Our evidence indicates that mast cell–associated MCPT4 contributes to the ability of mast cells to enhance resistance to the toxicity of both helodermin, the major VIP-like peptide in Gila monster venom, and mammalian VIP, the structurally similar endogenous peptide.

Local engraftment of mast cell–deficient mice with WT mast cells only at the site of venom or peptide injection enhanced resistance to the toxicity induced by Gila monster or scorpion venoms, helodermin, or VIP to a greater extent than did engraftment with Mcpt4–/– BMCMCs. Thus, a relatively small population of mast cells containing MCPT4 appears to be sufficient, at least if these cells are present at the site of envenomation, to increase the mouse’s ability to withstand the toxic effects of such venoms. Moreover, each of the venoms or toxic peptides tested induced extensive degranulation of skin mast cells at the site of injection. Finally, we found that WT mast cells were much more effective than Mcpt4–/– mast cells in degrading helodermin or VIP in vitro. Together, these findings indicate that mast cells can enhance host resistance to the toxicity of these lizard and scorpion venoms, or to helodermin or VIP, at least partly through the local release of MCPT4, which can then degrade venom components. In contrast, our experiments in mice whose CPA3 lacked catalytic activity, or in Cpa3–/– mice, which lack both CPA3 and MCPT5 proteins, indicate that CPA3 and MCPT5 make substantially less or no contribution to resistance to these particular venoms or toxic peptides.

We think that these findings help to illuminate how mast cells can influence 2 different areas of biology: (a) innate host resistance to animal venoms and (b) regulation of the toxicity of endogenous biologically active peptides. Host resistance to the toxicity of animal venoms probably reflects the contribution of many different factors (52, 53); however, the mast cell has only recently been shown to deserve a place on that list (6, 7). Indeed, the induction of mast cell degranulation at sites of envenomation until recently has been thought to contribute to the pathology induced by the venom (6, 54). Notably, Higginbotham proposed in 1965 that mast cell heparin might increase resistance to Russell’s viper venom (55) and in 1971 that mast cell heparin might also confer resistance to honeybee stings (56). Unfortunately, mast cell–deficient mice had not yet been reported when those studies were published, and the idea that mast cells conferred more benefit than harm in snake or honeybee envenomation only recently was tested (and confirmed) using mast cell–engrafted genetically mast cell–deficient mice (6). In the case of mice injected with A. engaddensis venom, several lines of evidence indicate that CPA3 is the major mast cell protease that enhances host resistance (6, 7). Pharmacological evidence suggests that CPA3 also contributes to the mouse mast cell–dependent enhancement of resistance to the venoms of the Western diamondback rattlesnake and the Southern copperhead (6).

In contrast, the evidence presented herein indicates that MCPT4 is more important than CPA3 in the mast cell–dependent enhancement of the resistance of mice to the venoms of the Gila monster or of 2 medically important scorpions, the deathstalker (yellow) scorpion (L. quinquestriatus hebraeus) and the Arizona bark scorpion (C. exilicauda). Taken together, our studies of the ability of mast cells to enhance resistance to the venoms of 3 poisonous snakes and 1 venomous lizard, as well as 3 venomous arthropods, suggest that the ability of mast cells to store and rapidly release large amounts of proteases with distinct profiles of substrate specificity may permit these cells to contribute to innate host defense against a variety of animal venoms containing diverse toxic substances. This, of course, does not rule out the possibility that the induction of mast cell degranulation by the venoms of some species of poisonous animals can increase the pathology associated with such envenomation. However, no such example has yet been reported based on studies in mice deficient in mast cells or individual mast cell–associated proteases.

Many animal venoms contain peptides that have structural and functional similarities to endogenous mammalian peptides (12, 57), and many of these venom-associated peptides can bind to the receptors for the corresponding mammalian peptides (58). It appears likely that convergent evolution, rather than an origin from a common ancestral gene, explains the presence of some of these peptides in reptile venoms, including helodermin (12) and sarafotoxin 6b (59). Indeed, helodermin has been detected only in the salivary glands of the Gila monster, whereas a VIP-like peptide that may represent a true ortholog of mammalian VIP can be detected in other Gila monster tissues (12). Thus, the ability of the Gila monster to concentrate large amounts of helodermin in its salivary secretions may have developed in large part so that the lizard’s venom can activate VIP receptors in cells of the lizard’s prey, with effects that induce disability or death in the prey animal.

Endogenous peptides such as VIP and ET-1 also can induce pathology when produced inappropriately and/or in excessively high amounts, and therefore it is important to have regulatory mechanisms to diminish the concentrations of such peptides or to counteract their effects. We previously reported evidence that mast cells can reduce the pathology and mortality associated with high levels of ET-1 (4, 6, 7) or neurotensin (5) by mechanisms that involve CPA3 (6, 7) or neurolysin (5), respectively. In the present study, we found that mast cell–associated MCPT4 can degrade VIP and reduce the hypothermia and diarrhea observed in mice injected with large amounts of this peptide.

There are at least 2 implications of these findings. First, they support the general hypothesis that the ability of mast cells to produce a diverse complement of enzymes may be useful in permitting these cells to reduce the potential toxicity of a variety of endogenous peptides that can activate mast cell degranulation when present in high enough concentrations, as well as to degrade and limit the toxicity of structurally and functionally similar peptides that are present in animal venoms. More specifically, our findings suggest that mast cell–dependent degradation of VIP may either help to limit the pathology associated with excessive levels of this peptide, such as when it is produced by a tumor (44, 45) and perhaps in other settings, and/or may contribute to pathology associated with abnormally low levels of this peptide. For example, reduced levels of VIP have been reported in the airways of patients with severe asthma (60), and VIP-deficient mice exhibit airway hyperresponsiveness and inflammation that can be partially rescued by administration of VIP (61). Taken together, these findings raise the possibility that mast cell–dependent degradation of VIP might contribute to pathology in some settings, including asthma.

Mast cells have long been viewed as important contributors to disease, both in the context of anaphylaxis and allergic diseases and in many other disorders (6265). The findings presented herein and in our prior work (47) indicate that the expression by mast cells of receptors for VIP, ET-1, neurotensin, and other endogenous peptides that can trigger mast cell degranulation, when combined with the mast cell’s ability to produce enzymes that can degrade these and related peptides, permits mast cells to contribute to health in 2 different contexts: reducing the toxicity associated with high concentrations of the endogenous peptides and limiting the pathology induced by structurally and functionally similar peptides contained in animal venoms. Indeed, we find it appealing to speculate that a mast cell–dependent mechanism that may have developed primarily to help to restore homeostasis in the face of conditions associated with elevated levels of peptides such as VIP and ET-1 (namely, the activation of mast cells by such peptides, inducing the release of proteases that can degrade the peptide) may also provide a selective advantage by enhancing host resistance to structurally and functionally similar peptides in animal venoms. It is tempting to speculate further that the occurrence of large numbers of mast cells in the skin, a frequent site of envenomation, in part reflects evolutionary pressure to position these cells where they can rapidly respond to, and thereby help to limit the toxicity of, the venoms of poisonous invertebrates and reptiles. Finally, the development of IgE antibodies to venom components has been reported for snake (6668), honeybee (6971), and scorpion (7274) venoms. It is well known that exposure of highly sensitized subjects to such venoms can result in anaphylaxis (68, 73, 75). However, the possibility should be considered that the presence of anti-venom IgE may further increase the ability of mast cell degranulation to enhance resistance to such venoms, at least in those subjects whose antibody-dependent reactions to such venoms stop short of anaphylaxis.

Methods

Mice.

c-Kit mutant genetically mast cell–deficient (WB/ReJ-Kit+/W × C57BL/6J-Kit+/W-v)F1-KitW/W-v (WBB6F1-KitW/W-v) mice, congenic normal WBB6F1-Kit+/+ (Kit+/+) mice, and C57BL/6J mice were purchased from Jackson Laboratory. C57BL/6-KitW-sh/W-sh mice were originally provided by Peter Besmer (Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA); these mice were then backcrossed to C57BL/6J mice for more than 11 generations. Mcpt4–/– mice (41), Cpa3–/– mice (51), and Cpa3Y356L,E378A mice (7) on the C57BL/6 background were bred and maintained at the Stanford University Research Animal Facility. Both adult KitW/W-v mice and adult KitW-sh/W-sh mice have a profound deficiency of mast cells, including less than 1% WT levels of mast cells in the skin (39, 76, 77). All animal care and experimentation were conducted in compliance with the guidelines of the NIH and with the specific approval of the Institutional Animal Care and Use Committee of Stanford University.

Mast cell engraftment.

Selective engraftment of mast cells in mast cell–deficient WBB6F1-KitW/W-v or C57BL/6-KitW-sh/W-sh mice was performed as described (39). Bone marrow cells derived from WBB6F1-Kit+/+, C57BL/6-Kit+/+, or C57BL/6-Mcpt4–/– mice (female, 4–6-week-old) were cultured in IL-3–containing medium for 4–6 weeks to generate cell populations that contained more than 95% immature mast cells. 2.0 × 106 BMCMCs were injected i.d. into each mouse (2 injections into 1 ear pinna; 1.0 × 106 cells in 25 μl DMEM per injection), and the recipients were used for experiments 6–8 weeks later.

Chemicals and venoms.

We purchased VIP and VIP6–28 (Bachem), H. suspectum venom (Sigma-Aldrich), helodermin (Abgent), L. quinquestriatus hebraeus venom (Latoxan), and C. exilicauda venom (Spider Pharm Inc.) from the manufacturers.

Measurement of VIP.

VIP levels in the supernatants were measured by ELISA in accordance with the manufacturer’s instructions (Bachem).

Histology and quantification of mast cells and mast cell degranulation.

Mice were sacrificed by CO2 inhalation, and samples of ear pinna were fixed in 10% (v/v) buffered formalin, embedded in paraffin (ensuring a cross-sectional orientation), cut into 4-μm–thick sections, and stained with 0.1% (v/v) toluidine blue, pH 1, for the detection of mast cells (cytoplasmic granules appeared purple). Sections were “coded” so the evaluator was not aware of their identity. Ear pinna mast cells were counted in 5–8 consecutive fields, each with dimensions of 760 × 1020 μm, with a ×10 microscope objective (final magnification, ×100), and mast cells per horizontal ear cartilage field length (mm) were counted by computer-generated image analysis (NIH ImageJ software, version 1.29×). Quantification was performed on the entire length of a strip of skin extending from the base to the tip of the ear pinna (about 8–13 mm). After intradermal engraftment of BMCMCs, KitW–s/hW-sh or KitW/W-v mice had mast cells from the base to the tip of the ear pinnae in an anatomical distribution similar to that of the native mast cell populations in the corresponding WT mice. Degranulation of mast cells in the ear pinna was quantified as previously described (78) in 1-μm–thick, Giemsa-stained, Epon-embedded sections examined at a final magnification of ×1000, with the results expressed as percentage of mast cells exhibiting evidence of degranulation scored as follows: extensive (>50% of granules in that cell exhibiting evidence of degranulation); moderate (10%–50% of granules in that cell exhibiting evidence of degranulation); and none (<10% of granules in that cell exhibiting evidence of degranulation).

Purification of PMCs.

Mice were sacrificed by CO2 inhalation. To harvest peritoneal cells, 10 ml of HBSS buffer containing 10 U/ml heparin and 10% FCS were injected into the peritoneal cavity, and the abdomen was massaged gently for 30–60 seconds. Peritoneal cells were layered onto 1.5 ml of 23% HistoDenz (Sigma-Aldrich) in HBSS buffer containing 10 U/ml heparin and 10% FCS and centrifuged at 469 g for 15 minutes at room temperature. After washing, cells were stained with toluidine blue, and PMCs represented 70%–90% of the cells recovered.

β-Hexosaminidase release assay.

We stimulated a total of 1 × 106 PMCs (from WT or Mcpt4–/– mice)/ml in Tyrode’s buffer (10 mM HEPES buffer [pH 7.4], 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1 mM MgCl2, 0.1% glucose, and 0.1% BSA [fraction V; Sigma-Aldrich]) with the indicated concentrations of helodermin, VIP, or A23187 calcium ionophore (Sigma-Aldrich) for 30 minutes at 37°C with or without pretreatment (10 minutes before) with the VIP receptor antagonist VIP6–28; supernatants were collected after centrifugation. We used supernatants from nonstimulated PMCs treated with 10 μl of 0.5% (v/v) Triton X-100 (Sigma-Aldrich) to determine the maximal (100%) cellular β-hexosaminidase content, to which the experimental samples were normalized. We calculated the percentage of β-hexosaminidase release using an enzyme immunoassay with p-nitrophenyl-N-acetyl-β-d-glucosamine (p-NAG; Sigma-Aldrich) substrate as follows: 10 μl of culture supernatant was added to the wells of a 96-well flat-bottomed plate. 50 μl of 1.3 mg/ml p-NAG solution in 100 mM sodium citrate, pH 4.5, was added, and the plate was incubated for 60 minutes at 37°C. We then added 150 μl of 200 mM glycine, pH 10.7, to stop the reaction and measured the OD405.

Measurement of VIP in sera and ear skin lysates.

Blood and ear tissue samples were obtained 30 minutes after i.d. injection into the right ear pinnae of 5 nmol of helodermin or VIP. We prepared ear skin lysates by sonicating finely chopped ear tissue in 400 μl T-PER EDTA-free lysis buffer (Pierce) containing protease inhibitors (Roche). Samples were frozen at –80°C overnight, then thawed and centrifuged at 16000 g for 20 minutes at 4°C; supernatants were collected. We measured VIP concentrations in the supernatants by ELISA (Bachem).

Fourier transform mass spectrometry.

Cleavage reactions of VIP and helodermin peptides were separated on a 150 mm × 0.075 mm Zorbax C18 reversed phase column (Agilent), with a 5 μM particle size and 300 Å pore size, run at a flow rate of 300 nl/min in 0.1% trifluoroacetic acid/water (A):0.1% trifluoroacetic acid/acetonitrile (B). The column was run on a gradient of 3% B to 30% B for 35 minutes, 35% B to 90% B for 10 minutes, held at 90% B for 2 minutes, then rapidly decreased to 3% B over 0.1 minute, and reequilibrated at 3% for 20 minutes. Eluted peptides were run on a Thermo LTQ-FT mass spectrometer using Fourier transform mass spectrometry (FTMS) + p ESI Full MS scanning mode, mass range 400–1800; FT resolution was set to 100,000. The monoisotopic masses of the major peaks were observed and then searched against the known sequence of VIP and helodermin peptides to identify the cleavage products. The identity of the cleavage products was confirmed with MS/MS fragmentation and spectral matching. To compare the experimental and control samples, extracted ion chromatograms were prepared for the major peaks in the experimental runs; then the same extracted ion chromatograms were used to compare to the control sample.

Statistics.

The differences in the percentages of groups of mice that died within 24 hours after injection with helodermin, VIP, or various venoms were compared by Fisher’s exact test, whereas ANOVA for repeated measures was used to assess differences in body temperature responses. Unless otherwise specified, all other data were tested for statistical significance using the unpaired 2-tailed Student’s t test or, to compare values for the extent of mast cell degranulation, the χ2 test. P < 0.05 was considered statistically significant.

Supplementary Material

Supplemental data:

Acknowledgments

We thank C. Liu for excellent technical assistance and members of the Galli, Pejler, and Rodewald laboratories for discussions. This study was supported by grants from the NIH (AI70813, AI23990, and CA72074 to S.J. Galli), the German Research Foundation (DFG Me 2668/2-1 to M. Metz), and the European Research Council grant agreement (no. 233074 to H.R. Rodewald) and the DFG (754-2-3 to H.R. Rodewald).

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2011;121(10):4180–4191. doi:10.1172/JCI46139.

References

1. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131–140. doi: 10.1034/j.1600-065X.2000.917305.x. [PubMed] [Cross Ref]
2. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol. 2007;19(1):31–38. doi: 10.1016/j.coi.2006.11.006. [PubMed] [Cross Ref]
3. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10(6):440–452. [PubMed]
4. Maurer M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature. 2004;432(7016):512–516. doi: 10.1038/nature03085. [PubMed] [Cross Ref]
5. Piliponsky AM, et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med. 2008;14(4):392–398. [PMC free article] [PubMed]
6. Metz M, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science. 2006;313(5786):526–530. doi: 10.1126/science.1128877. [PubMed] [Cross Ref]
7. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald HR. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med. 2007;204(11):2629–2639. doi: 10.1084/jem.20071262. [PMC free article] [PubMed] [Cross Ref]
8. Yamamura H, Nabe T, Kohno S, Ohata K. Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells. Eur J Pharmacol. 1994;257(3):235–242. doi: 10.1016/0014-2999(94)90134-1. [PubMed] [Cross Ref]
9. Vandermeers A, et al. Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom. FEBS Lett. 1984;166(2):273–276. doi: 10.1016/0014-5793(84)80094-0. [PubMed] [Cross Ref]
10. Robberecht P, et al. Evidence that helodermin, a newly extracted peptide from Gila monster venom, is a member of the secretin/VIP/PHI family of peptides with an original pattern of biological properties. FEBS Lett. 1984;166(2):277–282. doi: 10.1016/0014-5793(84)80095-2. [PubMed] [Cross Ref]
11. Hoshino M, et al. Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom. FEBS Lett. 1984;178(2):233–239. doi: 10.1016/0014-5793(84)80607-9. [PubMed] [Cross Ref]
12. Pohl M, Wank SA. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem. 1998;273(16):9778–9784. doi: 10.1074/jbc.273.16.9778. [PubMed] [Cross Ref]
13. Strimple PD, Tomassoni AJ, Otten EJ, Bahner D. Report on envenomation by a Gila monster (Heloderma suspectum) with a discussion of venom apparatus, clinical findings, and treatment. Wilderness Environ Med. 1997;8(2):111–116. doi: 10.1580/1080-6032(1997)008[0111:ROEBAG]2.3.CO;2. [PubMed] [Cross Ref]
14. Raufman JP. Bioactive peptides from lizard venoms. Regul Pept. 1996;61(1):1–18. doi: 10.1016/0167-0115(96)00135-8. [PubMed] [Cross Ref]
15. Piacentine J, Curry SC, Ryan PJ. Life-threatening anaphylaxis following gila monster bite. Ann Emerg Med. 1986;15(8):959–961. doi: 10.1016/S0196-0644(86)80686-2. [PubMed] [Cross Ref]
16. Bou-Abboud CF, Kardassakis DG. Acute myocardial infarction following a gila monster (Heloderma suspectum cinctum) bite. West J Med. 1988;148(5):577–579. [PMC free article] [PubMed]
17. Beck DD.Biology Of Gila Monsters And Beaded Lizards . Berkeley, California, USA: University of California Press; 2005.
18. Aird SD. Nucleoside composition of Heloderma venoms. Comp Biochem Physiol B Biochem Mol Biol. 2008;150(2):183–186. doi: 10.1016/j.cbpb.2008.02.012. [PubMed] [Cross Ref]
19. Heitschel S. Near death from a Gila monster bite. J Emerg Nurs. 1986;12(5):259–262. [PubMed]
20. Fry BG, et al. Novel venom proteins produced by differential domain-expression strategies in beaded lizards and gila monsters (genus Heloderma). Mol Biol Evol. 2010;27(2):395–407. doi: 10.1093/molbev/msp251. [PubMed] [Cross Ref]
21. Vandermeers A, et al. Chemical, immunological and biological properties of peptides like vasoactive-intestinal-peptide and peptide-histidine-isoleucinamide extracted from the venom of two lizards (Heloderma horridum and Heloderma suspectum). Eur J Biochem. 1987;164(2):321–327. doi: 10.1111/j.1432-1033.1987.tb11061.x. [PubMed] [Cross Ref]
22. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 1993;334(1):3–8. doi: 10.1016/0014-5793(93)81668-P. [PubMed] [Cross Ref]
23. Naruse S, et al. Helodermin has a VIP-like effect upon canine blood flow. Peptides. 1986;1(3):237–240. doi: 10.1016/0196-9781(80)90060-1. [PubMed] [Cross Ref]
24. Cutz E, Chan W, Track NS, Goth A, Said SI. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature. 1978;275(5681):661–662. doi: 10.1038/275661a0. [PubMed] [Cross Ref]
25. Goetzl EJ, Sreedharan SP, Turck CW. Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells. J Biol Chem. 1988;263(19):9083–9086. [PubMed]
26. Waschek JA, Bravo DT, Richards ML. High levels of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells. Regul Pept. 1995;60(2-3):149–157. doi: 10.1016/0167-0115(95)00124-7. [PubMed] [Cross Ref]
27. Schmidt-Choudhury A, et al. Stem cell factor influences neuro-immune interactions: the response of mast cells to pituitary adenylate cyclase activating polypeptide is altered by stem cell factor. Regul Pept. 1999;83(2-3):73–80. doi: 10.1016/S0167-0115(99)00054-3. [PubMed] [Cross Ref]
28. Groneberg DA, et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol. 2003;111(5):1099–1105. doi: 10.1067/mai.2003.1477. [PubMed] [Cross Ref]
29. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 2008;123(3):398–410. doi: 10.1111/j.1365-2567.2007.02705.x. [PubMed] [Cross Ref]
30. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther. 1988;244(1):133–137. [PubMed]
31. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol. 1990;3(1):27–32. [PubMed]
32. Weisel-Eichler A, Libersat F. Venom effects on monoaminergic systems. J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2004;190(9):683–690. [PubMed]
33. Amitai Y. Clinical manifestations and management of scorpion envenomation. Public Health Rev. 1998;26(3):257–263. [PubMed]
34. Ben-Abraham R, Eschel G, Winkler E, Weinbroum AA, Barzilay Z, Paret G. Triage for Leiurus quinquestriatus scorpion envenomation in children--is routine ICU hospitalization necessary? . Hum Exp Toxicol. 2000;19(12):663–666. doi: 10.1191/096032700666836486. [PubMed] [Cross Ref]
35. Chippaux JP, Goyffon M. Epidemiology of scorpionism: a global appraisal. Acta Trop. 2008;107(2):71–79. doi: 10.1016/j.actatropica.2008.05.021. [PubMed] [Cross Ref]
36. Likes K, Banner W, Jr, Chavez M. Centruroides exilicauda envenomation in Arizona. . West J Med. 1984;141(5):634–637. [PMC free article] [PubMed]
37. LoVecchio F, McBride C. Scorpion envenomations in young children in central Arizona. J Toxicol Clin Toxicol. 2003;41(7):937–940. doi: 10.1081/CLT-120026514. [PubMed] [Cross Ref]
38. Nakano T, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. . J Exp Med. 1985;162(3):1025–1043. doi: 10.1084/jem.162.3.1025. [PMC free article] [PubMed] [Cross Ref]
39. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant KitW-sh/W-sh mice as a model for investigating mast cell biology in vivo. . Am J Pathol. 2005;167(3):835–848. doi: 10.1016/S0002-9440(10)62055-X. [PubMed] [Cross Ref]
40. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol. 2007;95:167–255. [PubMed]
41. Tchougounova E, Pejler G, Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med. 2003;198(3):423–431. doi: 10.1084/jem.20030671. [PMC free article] [PubMed] [Cross Ref]
42. Serafin WE, et al. Cloning of the cDNA and gene for mouse mast cell protease 4. Demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat. J Biol Chem. 1991;266(3):1934–1941. [PubMed]
43. Huang RY, Blom T, Hellman L. Cloning and structural analysis of MMCP-1, MMCP-4 and MMCP-5, three mouse mast cell-specific serine proteases. Eur J Immunol. 1991;21(7):1611–1621. doi: 10.1002/eji.1830210706. [PubMed] [Cross Ref]
44. Krejs GJ. VIPoma syndrome. Am J Med. 1987;82(5B):37–48. [PubMed]
45. Park SK, O’Dorisio MS, O’Dorisio TM. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Baillieres Clin Gastroenterol. 1996;10(4):673–696. doi: 10.1016/S0950-3528(96)90018-4. [PubMed] [Cross Ref]
46. Fishbein VA, et al. A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Peptides. 1994;15(1):95–100. doi: 10.1016/0196-9781(94)90176-7. [PubMed] [Cross Ref]
47. Andersson MK, Karlson U, Hellman L. The extended cleavage specificity of the rodent beta-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. Mol Immunol. 2008;45(3):766–775. doi: 10.1016/j.molimm.2007.06.360. [PubMed] [Cross Ref]
48. Kunori Y, et al. Rodent alpha-chymases are elastase-like proteases. Eur J Biochem. 2002;269(23):5921–5930. doi: 10.1046/j.1432-1033.2002.03316.x. [PubMed] [Cross Ref]
49. Waern I, et al. Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol. 2009;183(10):6369–6376. doi: 10.4049/jimmunol.0900180. [PubMed] [Cross Ref]
50. Younan G, et al. The inflammatory response after an epidermal burn depends on the activities of mouse mast cell proteases 4 and 5. J Immunol. 2010;185(12):7681–7690. doi: 10.4049/jimmunol.1002803. [PMC free article] [PubMed] [Cross Ref]
51. Feyerabend TB, et al. Loss of histochemical identity in mast cells lacking carboxypeptidase A. Mol Cell Biol. 2005;25(14):6199–6210. doi: 10.1128/MCB.25.14.6199-6210.2005. [PMC free article] [PubMed] [Cross Ref]
52. Brodie ED 3rd, Brodie ED., Jr Predator-prey arms races. BioScience. 1999;49:557–568. doi: 10.2307/1313476. [Cross Ref]
53. Soong TW, Venkatesh B. Adaptive evolution of tetrodotoxin resistance in animals. Trends Genet. 2006;22(11):621–626. doi: 10.1016/j.tig.2006.08.010. [PubMed] [Cross Ref]
54. Rivera J. Snake bites and bee stings: the mast cell strikes back. Nat Med. 2006;12(9):999–1000. doi: 10.1038/nm0906-999. [PubMed] [Cross Ref]
55. Higginbotham RD. Mast cells and local resistance to Russell’s viper venom. J Immunol. 1965;95(5):867–875. [PubMed]
56. Higginbotham RD, Karnella S. The significance of the mast cell response to bee venom. J Immunol. 1971;106(1):233–240. [PubMed]
57. Fry BG. From genome to “venome”: molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. Genome Res. 2005;15(3):403–420. doi: 10.1101/gr.3228405. [PubMed] [Cross Ref]
58. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov. 2003;2(10):790–802. doi: 10.1038/nrd1197. [PubMed] [Cross Ref]
59. Takasaki C, Itoh Y, Onda H, Fujino M. Cloning and sequence analysis of a snake, Atractaspis engaddensis gene encoding sarafotoxin S6c. . Biochem Biophys Res Commun. 1992;189(3):1527–1533. doi: 10.1016/0006-291X(92)90249-K. [PubMed] [Cross Ref]
60. Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C, Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med. 1989;320(19):1244–1248. doi: 10.1056/NEJM198905113201904. [PubMed] [Cross Ref]
61. Szema AM, et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol. 2006;291(5):L880–L886. doi: 10.1152/ajplung.00499.2005. [PubMed] [Cross Ref]
62. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749–786. doi: 10.1146/annurev.immunol.21.120601.141025. [PubMed] [Cross Ref]
63. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7(2):93–104. doi: 10.1038/nri2018. [PubMed] [Cross Ref]
64. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci. 2008;49(1):7–19. doi: 10.1016/j.jdermsci.2007.09.009. [PMC free article] [PubMed] [Cross Ref]
65. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9(11):1215–1223. doi: 10.1038/ni.f.216. [PMC free article] [PubMed] [Cross Ref]
66. Wadee AA, Rabson AR. Development of specific IgE antibodies after repeated exposure to snake venom. J Allergy Clin Immunol. 1987;80(5):695–698. doi: 10.1016/0091-6749(87)90289-2. [PubMed] [Cross Ref]
67. Mosimann B, et al. Life–threatening reaction after viper bite: detection of venom–specific IgE by dot assay. Lancet. 1992;340(8812):174. [PubMed]
68. Reimers AR, Weber M, Muller UR. Are anaphylactic reactions to snake bites immunoglobulin E-mediated? Clin Exp Allergy. 2000;30(2):276–282. [PubMed]
69. Hoffman DR, Shipman WH. Allergens in bee venom. I. Separation and identification of the major allergens. J Allergy Clin Immunol. 1976;58(5):551–562. doi: 10.1016/0091-6749(76)90201-3. [PubMed] [Cross Ref]
70. Sobotka AK, Franklin RM, Adkinson NF, Jr, Valentine M, Baer H, Lichtenstein LM. Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol. 1976;57(1):29–40. doi: 10.1016/0091-6749(76)90076-2. [PubMed] [Cross Ref]
71. Kettner A, Henry H, Hughes GJ, Corradin G, Spertini F. IgE and T-cell responses to high-molecular weight allergens from bee venom. Clin Exp Allergy. 1999;29(3):394–401. doi: 10.1046/j.1365-2222.1999.00492.x. [PubMed] [Cross Ref]
72. Leynadier F, Hassani Y, Chabane MH, Benguedda AC, Abbadi MC, Guerin L. Allergic reactions to North African scorpion venom evaluated by skin test and specific IgE. J Allergy Clin Immunol. 1997;99(6 pt 1):851–853. doi: 10.1016/S0091-6749(97)80022-X. [PubMed] [Cross Ref]
73. Nugent JS, More DR, Hagan LL, Demain JG, Whisman BA, Freeman TM. Cross-reactivity between allergens in the venom of the common striped scorpion and the imported fire ant. J Allergy Clin Immunol. 2004;114(2):383–386. doi: 10.1016/j.jaci.2004.04.016. [PubMed] [Cross Ref]
74. More D, et al. Identification of allergens in the venom of the common striped scorpion. Ann Allergy Asthma Immunol. 2004;93(5):493–498. doi: 10.1016/S1081-1206(10)61418-4. [PubMed] [Cross Ref]
75. Fernandez J, Soriano V, Mayorga L, Mayor M. Natural history of Hymenoptera venom allergy in Eastern Spain. Clin Exp Allergy. 2005;35(2):179–185. doi: 10.1111/j.1365-2222.2005.02169.x. [PubMed] [Cross Ref]
76. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978;52(2):447–452. [PubMed]
77. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1–96. [PubMed]
78. Yano H, Wershil BK, Arizono N, Galli SJ. Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. J Clin Invest. 1989;84(4):1276–1286. doi: 10.1172/JCI114295. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation